{"id":1825,"date":"2014-03-21T10:21:12","date_gmt":"2014-03-21T10:21:12","guid":{"rendered":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/?p=1825"},"modified":"2014-03-21T13:29:43","modified_gmt":"2014-03-21T13:29:43","slug":"ueberaktive-blase-orale-anticholinergika-versus-injiziertes-onabotulinumtoxin","status":"publish","type":"post","link":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/ueberaktive-blase-orale-anticholinergika-versus-injiziertes-onabotulinumtoxin\/","title":{"rendered":"\u00dcberaktive Blase: orale Anticholinergika versus injiziertes Onabotulinumtoxin A"},"content":{"rendered":"<p>AMB 2013,\u00a047, 06 &nbsp; \u00dcberaktive Blase: orale Anticholinergika versus injiziertes Onabotulinumtoxin A Fazit:\u00a0Eine \u00fcberaktive Blase mit Dranginkontinenz kann bei Frauen durch zystoskopisch gesteuerte, einmalige Injektion von Botox in den Detrusormuskel \u00fcber einen Zeitraum von sechs Monaten \u00e4hnlich gebessert werden wie mit einer oralen &#8230;\u00a0\u00a0Bitte abonnieren oder Kennlernartikel anfordern &#8211;&gt; &nbsp; Schlagworte zum Artikel: ABC-Studie,\u00a0Anticholinergika,\u00a0Blasenschw\u00e4che,\u00a0Blasen\u00fcberaktivit\u00e4t,\u00a0Botulinumtoxin, Dranginkontinenz,\u00a0NOBLE-Studie,\u00a0Onabotulinumtoxin [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>AMB 2013,\u00a047, 06 &nbsp; \u00dcberaktive Blase: orale Anticholinergika versus injiziertes Onabotulinumtoxin A Fazit:\u00a0Eine \u00fcberaktive Blase mit Dranginkontinenz kann bei Frauen durch zystoskopisch gesteuerte, einmalige Injektion von Botox in den Detrusormuskel \u00fcber einen Zeitraum von sechs Monaten \u00e4hnlich gebessert werden wie mit einer oralen &#8230;\u00a0\u00a0Bitte abonnieren oder Kennlernartikel anfordern &#8211;&gt; &nbsp; Schlagworte zum Artikel: ABC-Studie,\u00a0Anticholinergika,\u00a0Blasenschw\u00e4che,\u00a0Blasen\u00fcberaktivit\u00e4t,\u00a0Botulinumtoxin, Dranginkontinenz,\u00a0NOBLE-Studie,\u00a0Onabotulinumtoxin [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","footnotes":""},"categories":[24,25],"tags":[970,971,972,973,974,975,976,977,978,979,980],"class_list":["post-1825","post","type-post","status-publish","format-standard","hentry","category-jahr-2013-band-47","category-monat-01","tag-abc-studie","tag-anticholinergika","tag-blasenschwaeche","tag-blasenueberaktivitaet","tag-botulinumtoxin","tag-dranginkontinenz","tag-noble-studie","tag-onabotulinumtoxin-a","tag-solifenacin","tag-trospiumchlorid","tag-urininkontinenz"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>\u00dcberaktive Blase: orale Anticholinergika versus injiziertes Onabotulinumtoxin A<\/title>\n<meta name=\"description\" content=\"\u00dcberaktive Blase: orale Anticholinergika versus injiziertes Onabotulinumtoxin A - UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken --&gt;\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/ueberaktive-blase-orale-anticholinergika-versus-injiziertes-onabotulinumtoxin\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\u00dcberaktive Blase: orale Anticholinergika versus injiziertes Onabotulinumtoxin A\" \/>\n<meta property=\"og:description\" content=\"\u00dcberaktive Blase: orale Anticholinergika versus injiziertes Onabotulinumtoxin A - UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken --&gt;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/ueberaktive-blase-orale-anticholinergika-versus-injiziertes-onabotulinumtoxin\/\" \/>\n<meta property=\"og:site_name\" content=\"Der Arzneimittelbrief\" \/>\n<meta property=\"article:publisher\" content=\"http:\/\/www.facebook.com\/derarzneimittelbrief.de\" \/>\n<meta property=\"article:published_time\" content=\"2014-03-21T10:21:12+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2014-03-21T13:29:43+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg\" \/>\n<meta name=\"author\" content=\"henk-amb\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"henk-amb\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"1\u00a0Minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/ueberaktive-blase-orale-anticholinergika-versus-injiziertes-onabotulinumtoxin\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/ueberaktive-blase-orale-anticholinergika-versus-injiziertes-onabotulinumtoxin\\\/\"},\"author\":{\"name\":\"henk-amb\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/2e7981c97826a4941311e607c145d937\"},\"headline\":\"\u00dcberaktive Blase: orale Anticholinergika versus injiziertes Onabotulinumtoxin A\",\"datePublished\":\"2014-03-21T10:21:12+00:00\",\"dateModified\":\"2014-03-21T13:29:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/ueberaktive-blase-orale-anticholinergika-versus-injiziertes-onabotulinumtoxin\\\/\"},\"wordCount\":259,\"image\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/ueberaktive-blase-orale-anticholinergika-versus-injiziertes-onabotulinumtoxin\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2014\\\/01\\\/GPSP_Banner_AMB_01_2013.jpg\",\"keywords\":[\"ABC-Studie\",\"Anticholinergika\",\"Blasenschw\u00e4che\",\"Blasen\u00fcberaktivit\u00e4t\",\"Botulinumtoxin\",\"Dranginkontinenz\",\"NOBLE-Studie\",\"Onabotulinumtoxin A\",\"Solifenacin\",\"Trospiumchlorid\",\"Urininkontinenz\"],\"articleSection\":[\"Jahr 2013 Band 47\",\"Monat 01\"],\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/ueberaktive-blase-orale-anticholinergika-versus-injiziertes-onabotulinumtoxin\\\/\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/ueberaktive-blase-orale-anticholinergika-versus-injiziertes-onabotulinumtoxin\\\/\",\"name\":\"\u00dcberaktive Blase: orale Anticholinergika versus injiziertes Onabotulinumtoxin A\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/ueberaktive-blase-orale-anticholinergika-versus-injiziertes-onabotulinumtoxin\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/ueberaktive-blase-orale-anticholinergika-versus-injiziertes-onabotulinumtoxin\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2014\\\/01\\\/GPSP_Banner_AMB_01_2013.jpg\",\"datePublished\":\"2014-03-21T10:21:12+00:00\",\"dateModified\":\"2014-03-21T13:29:43+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/2e7981c97826a4941311e607c145d937\"},\"description\":\"\u00dcberaktive Blase: orale Anticholinergika versus injiziertes Onabotulinumtoxin A - UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken -->\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/ueberaktive-blase-orale-anticholinergika-versus-injiziertes-onabotulinumtoxin\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/ueberaktive-blase-orale-anticholinergika-versus-injiziertes-onabotulinumtoxin\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/ueberaktive-blase-orale-anticholinergika-versus-injiziertes-onabotulinumtoxin\\\/#primaryimage\",\"url\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2014\\\/01\\\/GPSP_Banner_AMB_01_2013.jpg\",\"contentUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2014\\\/01\\\/GPSP_Banner_AMB_01_2013.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/ueberaktive-blase-orale-anticholinergika-versus-injiziertes-onabotulinumtoxin\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Start\",\"item\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\u00dcberaktive Blase: orale Anticholinergika versus injiziertes Onabotulinumtoxin A\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\",\"name\":\"Der Arzneimittelbrief\",\"description\":\"Unabh\u00e4ngige Arzneimittelinformationen\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/2e7981c97826a4941311e607c145d937\",\"name\":\"henk-amb\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g\",\"caption\":\"henk-amb\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u00dcberaktive Blase: orale Anticholinergika versus injiziertes Onabotulinumtoxin A","description":"\u00dcberaktive Blase: orale Anticholinergika versus injiziertes Onabotulinumtoxin A - UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken -->","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/ueberaktive-blase-orale-anticholinergika-versus-injiziertes-onabotulinumtoxin\/","og_locale":"de_DE","og_type":"article","og_title":"\u00dcberaktive Blase: orale Anticholinergika versus injiziertes Onabotulinumtoxin A","og_description":"\u00dcberaktive Blase: orale Anticholinergika versus injiziertes Onabotulinumtoxin A - UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken -->","og_url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/ueberaktive-blase-orale-anticholinergika-versus-injiziertes-onabotulinumtoxin\/","og_site_name":"Der Arzneimittelbrief","article_publisher":"http:\/\/www.facebook.com\/derarzneimittelbrief.de","article_published_time":"2014-03-21T10:21:12+00:00","article_modified_time":"2014-03-21T13:29:43+00:00","og_image":[{"url":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg","type":"","width":"","height":""}],"author":"henk-amb","twitter_misc":{"Verfasst von":"henk-amb","Gesch\u00e4tzte Lesezeit":"1\u00a0Minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/ueberaktive-blase-orale-anticholinergika-versus-injiziertes-onabotulinumtoxin\/#article","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/ueberaktive-blase-orale-anticholinergika-versus-injiziertes-onabotulinumtoxin\/"},"author":{"name":"henk-amb","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/2e7981c97826a4941311e607c145d937"},"headline":"\u00dcberaktive Blase: orale Anticholinergika versus injiziertes Onabotulinumtoxin A","datePublished":"2014-03-21T10:21:12+00:00","dateModified":"2014-03-21T13:29:43+00:00","mainEntityOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/ueberaktive-blase-orale-anticholinergika-versus-injiziertes-onabotulinumtoxin\/"},"wordCount":259,"image":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/ueberaktive-blase-orale-anticholinergika-versus-injiziertes-onabotulinumtoxin\/#primaryimage"},"thumbnailUrl":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg","keywords":["ABC-Studie","Anticholinergika","Blasenschw\u00e4che","Blasen\u00fcberaktivit\u00e4t","Botulinumtoxin","Dranginkontinenz","NOBLE-Studie","Onabotulinumtoxin A","Solifenacin","Trospiumchlorid","Urininkontinenz"],"articleSection":["Jahr 2013 Band 47","Monat 01"],"inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/ueberaktive-blase-orale-anticholinergika-versus-injiziertes-onabotulinumtoxin\/","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/ueberaktive-blase-orale-anticholinergika-versus-injiziertes-onabotulinumtoxin\/","name":"\u00dcberaktive Blase: orale Anticholinergika versus injiziertes Onabotulinumtoxin A","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/ueberaktive-blase-orale-anticholinergika-versus-injiziertes-onabotulinumtoxin\/#primaryimage"},"image":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/ueberaktive-blase-orale-anticholinergika-versus-injiziertes-onabotulinumtoxin\/#primaryimage"},"thumbnailUrl":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg","datePublished":"2014-03-21T10:21:12+00:00","dateModified":"2014-03-21T13:29:43+00:00","author":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/2e7981c97826a4941311e607c145d937"},"description":"\u00dcberaktive Blase: orale Anticholinergika versus injiziertes Onabotulinumtoxin A - UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken -->","breadcrumb":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/ueberaktive-blase-orale-anticholinergika-versus-injiziertes-onabotulinumtoxin\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/ueberaktive-blase-orale-anticholinergika-versus-injiziertes-onabotulinumtoxin\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/ueberaktive-blase-orale-anticholinergika-versus-injiziertes-onabotulinumtoxin\/#primaryimage","url":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg","contentUrl":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/ueberaktive-blase-orale-anticholinergika-versus-injiziertes-onabotulinumtoxin\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Start","item":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/"},{"@type":"ListItem","position":2,"name":"\u00dcberaktive Blase: orale Anticholinergika versus injiziertes Onabotulinumtoxin A"}]},{"@type":"WebSite","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/","name":"Der Arzneimittelbrief","description":"Unabh\u00e4ngige Arzneimittelinformationen","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Person","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/2e7981c97826a4941311e607c145d937","name":"henk-amb","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/secure.gravatar.com\/avatar\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g","caption":"henk-amb"}}]}},"_links":{"self":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/1825","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/comments?post=1825"}],"version-history":[{"count":5,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/1825\/revisions"}],"predecessor-version":[{"id":1837,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/1825\/revisions\/1837"}],"wp:attachment":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/media?parent=1825"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/categories?post=1825"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/tags?post=1825"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}